ALK and non-small cell lung carcinoma: Our results suggest that RIB fits into EML4-ALK protein as a potent ATP-competitive molecule due to higher binding energy metrics than ATP and, although it is lower than other FDA-approved iALK, it seems attractive as a potential pharmacological subject of study for ALK+ NSCLC patients.